Freqency of Carnitine Deficiency in Patients with Chronic Liver Disease, and Efficacy of Oral L-Carnitine Treatment for Patiens with Liver Cirrhosis
Not Applicable
Completed
- Conditions
- Simple fatty liver, non-alcohoic steatohepatitis, alcoholic liver disease, and liver cirrhosis
- Registration Number
- JPRN-UMIN000013787
- Lead Sponsor
- Kansai Study Group of Liver Steatosis(KASALS)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1) Pregnant and lactating females 2) Hisotry of drug allergy 3) Inappropriate for entry onto this study in the judgment of the investigator 4) Administration of other test drugs within 1 month
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie carnitine deficiency in chronic liver disease patients?
How does oral L-carnitine compare to standard-of-care in managing liver cirrhosis symptoms?
Which biomarkers correlate with carnitine deficiency severity in non-alcoholic steatohepatitis?
What adverse events are associated with long-term L-carnitine supplementation in alcoholic liver disease?
Are there combination therapies involving L-carnitine for improving outcomes in fatty liver disease?